ArticleJournal of radiation research2026
Blood dose estimates in radiotherapy and correlations with adverse clinical outcomes in hepatocellular carcinoma.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiation-induced remodeling of the T cell landscape in head and neck cancer.Cancer immunology, immunotherapy : CII · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aims to investigate the potential correlation between the hematological dose (HEDOS), representing the dynamic blood dose, and severe radiation-induced lymphopenia (SRIL). The study examines whether SRIL mediates the relationship between HEDOS and oncologic outcomes in patients with hepatocellular carcinoma (HCC). A total of 41 patients with HCC who received radiation therapy to the liver and/or perihepatic metastatic lesions were retrospectively analyzed. Blood-related organs (spleen, heart, veins, aortas, lungs, and liver) were manually delineated. HEDOS was calculated using a Markov chain model. The effective dose to immune cells (EDIC), representing the static blood dose, was calculated for comparison with HEDOS. We examined whether these two blood dose metrics correlated with SRIL, defined as an absolute lymphocyte count below 500/μL one month after radiotherapy. The association between blood dose metrics and clinical outcomes, local and distant recurrence-free survival (LFS and DFS) was also evaluated. The mean HEDOS was significantly associated with SRIL, with an odds ratio of 1.61 (95% confidence interval [CI]: 1.10-2.54, P = 0.02). The mean HEDOS was associated with worse LFS and DFS, with hazard ratios of 1.35 (95% CI: 1.06-1.71, P = 0.01) for LFS and 1.28 (95% CI: 1.01-1.63, P = 0.04) for DFS. No association was observed between EDIC and any of the outcomes. A higher mean HEDOS showed a statistically significant correlation with SRIL and clinical outcomes, whereas the EDIC did not. The HEDOS, which incorporates temporal delivery characteristics such as dose rate and beam-on-time, may have an advantage for predicting SRIL and clinical outcomes of patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.